Branded Generics Market - Global Industry Analysis

Branded Generics Market by Therapeutic Application (Cardiovascular Diseases, Oncology, Diabetes, Gastrointestinal Diseases, Neurology, Analgesics and Anti-Inflammatory, Dermatology Diseases, Others) by Drug Class (Alkylating Agents, Hormones, Antimetabolites, Anti-Hypertensive, Anti-Depressants, Lipid Lowering Drugs, Anti-Epileptics, Anti-Psychotics, Others) by Formulation Type (Oral, Topical, Parenteral, Others) by Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2026

Published Date: 19-Mar-2021 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-5992 Status : Published

The branded generics market is set for a rapid growth over the forecast period. In terms of revenue, the global branded generics market accounted for USD 248.55 Billion in 2019 and is expected to reach USD 453.63 Billion by 2026, growing at a CAGR of 8.98%.

Description

The branded generics market is set for a rapid growth over the forecast period. In terms of revenue, the global branded generics market accounted for USD 248.55 Billion in 2019 and is expected to reach USD 453.63 Billion by 2026, growing at a CAGR of 8.98%.

Global Branded Generics Market: Overview

Branded generics are generic medicines that have a proprietary brand name. They may be sold in the same way as generic drugs. Ordinary generic medicines are usually identified by their chemical names. Trimox is a patented drug that is also available as ‘amoxicillin’ which is its generic name. Branded generics, on the other hand, are granted names in order to increase market awareness and loyalty. Cryselle, for example, is a branded generic birth control pill. To increase the probability of patients requesting it by name, it is referred to as Cryselle rather than its chemical name (Ethinyl estradiol and norgestrel).

Some branded generics are created as novel dosage forms of off-patent medicines, filling a dosage gap and providing customers with a name that is usually much easier to recall than its generic name. Branded generics constitute a small but lucrative segment of the pharmaceutical industry.

It's common to mix up branded generics and licensed generics, but they're not the same thing. After branded drug patents expire, branded generics must go through the same FDA approval process as other generics. Authorized generics, on the other hand, are produced by branded drug manufacturers under the same New Drug Approval (NDA) authorization as the actual branded drug, and they can be marketed before drug patents expire. In terms of cost, both branded generics and licensed generics are more expensive than standard generics but less expensive than branded drug/medicine with unexpired drug patents.

In the United States, branded generics receive more than unbranded generics, although they account for a small proportion of total generic prescriptions. Branded generics were 13 times more costly than unbranded generics in 2018 and accounted for 21% of all generic drugs. In other words, they represent a limited but profitable segment of the overall generic market.

Preferred branded generics can differ from supplier to supplier and pharmacy to pharmacy. While manufacturers do not advertise or promote branded generics, they do build relationships with retailers that favour these drugs over unbranded generics.

Branded generics are becoming more common in low- and middle-income countries, which can complicate market differentiation in terms of product and price. In the past, Pharmacy Benefit Managers (PBMs) in the United States have been accused of deliberately misclassifying medications in order to obtain brand rates for generics or higher rebates for specific generic products.

To ensure cost savings, formulary managers must regularly monitor the medications on their formularies. Branded generics, like generics, offer alternatives to branded medications and often result in cost savings. However, there is some disagreement between formulary managers and PBMs about how PBMs avoid revenue disclosures. Some pharmacy benefit consultants claim that branded generics are one way for PBMs to hide sales.

Global Branded Generics Market: Growth Factors

Off-invoice discounts would drive growth in the global branded generics market over the forecast period. Because of higher discounts offered by players, demand for branded generic drugs is expected to be strong in established markets such as the United States. In recent years, the global branded generics market has expanded at an unprecedented rate. Several intrinsic and extrinsic dynamics relating to licencing, production, and distribution characterise the pharmaceutical industry. The principle of patenting is highly useful in the pharmaceutical industry. Drugs patented to a specific company grant the entity legal rights to sell the product in the pharmaceutical industry. Furthermore, by patenting their products, pharmaceutical companies will remain unaffected by the emergence of numerous rivals in the industry. However, the idea of branded generics has grown in the pharmaceutical industry in recent years. Since branded generics can be off-patient, many pharmaceutical firms will bid to sell these drugs on the market.

Global Branded Generics Market: Segmentation

Cardiac arrests, hypertension, and diabetes account for a large proportion of all global fatalities. There has been an increase in the demand for anti-hypertensive drugs from all over the world. This necessitates the availability of low-cost medicines, and branded generics have proved to be a practical alternative.

Despite the fact that oral formulations account for more than half of the branded generics industry sales, “Parenteral Formulation” may escort to a new part in near future. Parenteral formulation adoption is expected to rise at a rapid pace during the forecast period.

The demand for branded generic lipid-lowering drugs is increasing as obesity is growing at an exponential pace. According to the Centers for Disease Control and Prevention (CDC), the number of obese citizens in the United States has almost doubled in the last decade. Market participants are eager to move to a lipid-lowering mode in order to promote weight loss. One such lipid-lowering medicine is generic Atorvastatin. Similarly, others will join the fray during the forecast era.

Global Branded Generics Market: Regional Analysis

By Geography, the branded generics market is segmented into North America, Europe, Latin America, Asia Pacific, and Middle East and Africa.

Latin America has emerged as a top priority for the pharmaceutical industry. The barriers to entry are smaller than in China and Russia. Significant disparities in healthcare systems, intellectual property structures, and emerging middle-class income, on the other hand, necessitate a country-by-country evaluation of attractiveness. The top six Latin American pharmaceuticals markets – Brazil, Mexico, Venezuela, Argentina, Colombia, and Chile – account for 80% of the industry, but their economic conditions vary greatly. Brazil and Mexico are the most stable and sought-after prospects, but they also necessitate significant investment.

As a result, some multinational corporations have shifted their attention to medium-sized countries such as Columbia, which they are primarily entering through Mergers and Acquisitions (M&A). However, an industry consensus on the attractiveness of markets such as Colombia, Venezuela, and Argentina are yet to emerge, and several multinationals are still analysing the potential. Local businesses in Argentina, for example, can be extremely competitive and profitable, whereas multinational corporations struggle. As in all emerging markets, the secret to success is fully understanding local rules and customising the approach to local needs while capturing regional synergies.

China's pharmaceutical industry is highly fragmented, with over 4,000 drug producers. Market access is complicated and skewed in favour of local players. Many global generics players have entered China, either alone or through joint ventures, but these moves appear to be small-scale experiments to see what approach would be fruitful. China is a highly profitable market for originators. The overall field force for the top ten global prescription drug firms has risen massively compared to past, though at lower productivity levels. Global generics firms, on the other hand, are struggling. Slow registrations, trouble winning highly competitive provincial tenders, and hospital listing criteria all make it difficult for them to gain market share. All these factors are heavily contributing to the growth of branded generics in these countries.

Global Branded Generics Market: Competitive Players

The major players in the global branded generics market include Teva Pharmaceutical Industries Ltd., Mylan N.V, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Abbott Laboratories, Aspen Pharmacare Holding Ltd., and Valeant Pharmaceuticals International, Inc. among others.

The report segment of global branded generics market are as follows:

Global Branded Generics Market: Therapeutic Application Segment Analysis

  • Cardiovascular Diseases
  • Oncology
  • Gastrointestinal Diseases
  • Neurology
  • Analgesics and Anti-Inflammatory
  • Diabetes
  • Dermatology Diseases
  • Others

Global Branded Generics Market: Drug Class Segment Analysis

  • Alkylating Agents
  • Hormones
  • Antimetabolites
  • Anti-Hypertensive
  • Anti-Depressants
  • Lipid Lowering Drugs
  • Anti-Epileptics
  • Anti-Psychotics
  • Others

Global Branded Generics Market: Formulation Type Segment Analysis

  • Oral
  • Topical
  • Parenteral
  • Others

Global Branded Generics Market: Distribution Channel Segment Analysis

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Drug Stores

Global Branded Generics Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description
      • 1.1.1. Objective
      • 1.1.2. Target Audience
      • 1.1.3. Unique Selling Proposition (USP) & Offerings
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
      • 1.3.3. Level 1: Primary Research
      • 1.3.4. Level 2: Secondary Research
      • 1.3.5. Level 3: Data Validation and Expert Panel Assessment Report Description and Scope
  • Chapter 2. Executive Summary
    • 2.1. Global Branded Generics Market, 2016-2026, (USD Billion)
    • 2.2. Branded Generics Market: Market Snapshot
  • Chapter 3. Global Branded Generics Market – Industry Analysis
    • 3.1. Introduction
    • 3.2. Industry Ecosystem Analysis
    • 3.3. Technology Landscape
    • 3.4. Market Drivers
      • 3.4.1. North America
      • 3.4.2. Europe
      • 3.4.3. Asia Pacific
      • 3.4.4. Latin America
      • 3.4.5. MEA
    • 3.5. Restraints
    • 3.6. Opportunity
    • 3.7. Innovation & Sustainability
    • 3.8. Regulatory Landscape
    • 3.9. Porter’s Five Forces Analysis
    • 3.10. PESTLE Analysis
    • 3.11. Branded Generics Market: Market Attractiveness Analysis
      • 3.11.1. Market Attractiveness Analysis by Therapeutic Application Segment
      • 3.11.2. Market Attractiveness Analysis by Drug Class Segment
      • 3.11.3. Market Attractiveness Analysis by Formulation Type Segment
      • 3.11.4. Market Attractiveness Analysis by Distribution Channel Segment
  • Chapter 4. Global Branded Generics Market - Competitive Landscape
    • 4.1. Company Market Share Analysis, 2019
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions and Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Cullaborations and Joint Ventures
      • 4.2.4. Research & Development and Regional Expansion
  • Chapter 5. Branded Generics Market – Therapeutic Application Segment Analysis
    • 5.1. Global Branded Generics Market Revenue Share, by Therapeutic Application, 2019 & 2026 (USD Billion)
    • 5.2. Global Branded Generics Market by Cardiovascular Diseases, 2016 – 2026 (USD Billion)
    • 5.3. Global Branded Generics Market by Onculogy, 2016 – 2026 (USD Billion)
    • 5.4. Global Branded Generics Market by Diabetes, 2016 – 2026 (USD Billion)
    • 5.5. Global Branded Generics Market by Gastrointestinal Diseases, 2016 – 2026 (USD Billion)
    • 5.6. Global Branded Generics Market by Neurulogy, 2016 – 2026 (USD Billion)
    • 5.7. Global Branded Generics Market by Analgesics and Anti-Inflammatory, 2016 – 2026 (USD Billion)
    • 5.8. Global Branded Generics Market by Dermatulogy Diseases, 2016 – 2026 (USD Billion)
    • 5.9. Global Branded Generics Market by Others, 2016 – 2026 (USD Billion)
  • Chapter 6. Branded Generics Market – Drug Class Segment Analysis
    • 6.1. Global Branded Generics Market Revenue Share, by Drug Class, 2019 & 2026 (USD Billion)
    • 6.2. Global Branded Generics Market by Alkylating Agents, 2016 – 2026 (USD Billion)
    • 6.3. Global Branded Generics Market by Hormones, 2016 – 2026 (USD Billion)
    • 6.4. Global Branded Generics Market by Antimetabulites, 2016 – 2026 (USD Billion)
    • 6.5. Global Branded Generics Market by Anti-Hypertensive, 2016 – 2026 (USD Billion)
    • 6.6. Global Branded Generics Market by Anti-Depressants, 2016 – 2026 (USD Billion)
    • 6.7. Global Branded Generics Market by Lipid Lowering Drugs, 2016 – 2026 (USD Billion)
    • 6.8. Global Branded Generics Market by Anti-Epileptics, 2016 – 2026 (USD Billion)
    • 6.9. Global Branded Generics Market by Anti-Psychotics, 2016 – 2026 (USD Billion)
    • 6.10. Global Branded Generics Market by Others, 2016 – 2026 (USD Billion)
  • Chapter 7. Branded Generics Market – Formulation Type Segment Analysis
    • 7.1. Global Branded Generics Market Revenue Share, by Formulation Type, 2019 & 2026 (USD Billion)
    • 7.2. Global Branded Generics Market by Oral, 2016 – 2026 (USD Billion)
    • 7.3. Global Branded Generics Market by Topical, 2016 – 2026 (USD Billion)
    • 7.4. Global Branded Generics Market by Parenteral, 2016 – 2026 (USD Billion)
    • 7.5. Global Branded Generics Market by Others, 2016 – 2026 (USD Billion)
  • Chapter 8. Branded Generics Market – Distribution Channel Segment Analysis
    • 8.1. Global Branded Generics Market Revenue Share, by Distribution Channel, 2019 & 2026 (USD Billion)
    • 8.2. Global Branded Generics Market by Hospital Pharmacies, 2016 – 2026 (USD Billion)
    • 8.3. Global Branded Generics Market by Online Pharmacies, 2016 – 2026 (USD Billion)
    • 8.4. Global Branded Generics Market by Retail Pharmacies, 2016 – 2026 (USD Billion)
    • 8.5. Global Branded Generics Market by Drug Stores, 2016 – 2026 (USD Billion)
  • Chapter 9. Branded Generics Market - Regional Analysis
    • 9.1. Global Branded Generics Market: Regional Overview
      • 9.1.1. Global Branded Generics Market Revenue Share, By Region, 2019 & 2026 (USD Billion)
    • 9.2. North America
      • 9.2.1. North America Branded Generics Market Revenue 2016 – 2026 (USD Billion)
      • 9.2.2. North America Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion)
      • 9.2.3. North America Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
      • 9.2.4. North America Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
      • 9.2.5. North America Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.2.6. U.S.
        • 9.2.6.1. U.S. Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.2.6.2. U.S. Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.2.6.3. U.S. Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.2.6.4. U.S. Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.2.7. Canada
        • 9.2.7.1. Canada Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.2.7.2. Canada Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.2.7.3. Canada Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.2.7.4. Canada Education & Learning Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.2.8. Mexico
        • 9.2.8.1. Mexico Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.2.8.2. Mexico Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.2.8.3. Mexico Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.2.8.4. Mexico Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 9.3. Europe
      • 9.3.1. Europe Branded Generics Market Revenue 2016 – 2026 (USD Billion)
      • 9.3.2. Europe Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion)
      • 9.3.3. Europe Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
      • 9.3.4. Europe Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
      • 9.3.5. Europe Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.3.6. UK
        • 9.3.6.1. UK Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.3.6.2. UK Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.3.6.3. UK Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.3.6.4. UK Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.3.7. France
        • 9.3.7.1. France Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.3.7.2. France Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.3.7.3. France Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.3.7.4. France Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.3.8. Germany
        • 9.3.8.1. Germany Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.3.8.2. Germany Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.3.8.3. Germany Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.3.8.4. Germany Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.3.9. Italy
        • 9.3.9.1. Italy Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.3.9.2. Italy Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.3.9.3. Italy Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.3.9.4. Italy Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.3.10. Spain
        • 9.3.10.1. Spain Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.3.10.2. Spain Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.3.10.3. Spain Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.3.10.4. Spain Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.3.11. Russia
        • 9.3.11.1. Russia Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.3.11.2. Russia Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.3.11.3. Russia Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.3.11.4. Russia Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.3.12. Rest of Europe
        • 9.3.12.1. Rest of Europe Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.3.12.2. Rest of Europe Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.3.12.3. Rest of Europe Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.3.12.4. Rest of Europe Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific Branded Generics Market Revenue 2016 – 2026 (USD Billion)
      • 9.4.2. Asia Pacific Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion)
      • 9.4.3. Asia Pacific Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
      • 9.4.4. Asia Pacific Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
      • 9.4.5. Asia Pacific Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.4.6. China
        • 9.4.6.1. China Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.4.6.2. China Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.4.6.3. China Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.4.6.4. China Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.4.7. Japan
        • 9.4.7.1. Japan Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.4.7.2. Japan Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.4.7.3. Japan Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.4.7.4. Japan Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.4.8. India
        • 9.4.8.1. India Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.4.8.2. India Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.4.8.3. India Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.4.8.4. India Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.4.9. Australia
        • 9.4.9.1. Australia Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.4.9.2. Australia Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.4.9.3. Australia Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.4.9.4. Australia Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.4.10. South Korea
        • 9.4.10.1. South Korea Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.4.10.2. South Korea Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.4.10.3. South Korea Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.4.10.4. South Korea Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.4.11. Rest of Asia Pacific
        • 9.4.11.1. Rest of Asia Pacific Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.4.11.2. Rest of Asia Pacific Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.4.11.3. Rest of Asia Pacific Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.4.11.4. Rest of Asia Pacific Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 9.5. Latin America
      • 9.5.1. Latin America Branded Generics Market Revenue 2016 – 2026 (USD Billion)
      • 9.5.2. Latin America Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion)
      • 9.5.3. Latin America Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
      • 9.5.4. Latin America Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
      • 9.5.5. Latin America Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.5.6. Brazil
        • 9.5.6.1. Brazil Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.5.6.2. Brazil Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.5.6.3. Brazil Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.5.6.4. Brazil Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.5.7. Argentina
        • 9.5.7.1. Argentina Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.5.7.2. Argentina Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.5.7.3. Argentina Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.5.7.4. Argentina Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.5.8. Rest of Latin America
        • 9.5.8.1. Rest of Latin America Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.5.8.2. Rest of Latin America Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.5.8.3. Rest of Latin America Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.5.8.4. Rest of Latin America Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 9.6. Middle East & Africa
      • 9.6.1. Middle East & Africa Branded Generics Market Revenue 2016 – 2026 (USD Billion)
      • 9.6.2. Middle East & Africa Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
      • 9.6.3. Middle East & Africa Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
      • 9.6.4. Middle East & Africa Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
      • 9.6.5. Middle East & Africa Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.6.6. GCC Countries
        • 9.6.6.1. GCC Countries Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.6.6.2. GCC Countries Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.6.6.3. GCC Countries Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.6.6.4. GCC Countries Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.6.7. South Africa
        • 9.6.7.1. South Africa Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.6.7.2. South Africa Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.6.7.3. South Africa Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.6.7.4. South Africa Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
      • 9.6.8. Rest of MEA
        • 9.6.8.1. Rest of MEA Branded Generics Market Revenue, by Therapeutic Application, 2016 – 2026 (USD Billion)
        • 9.6.8.2. Rest of MEA Branded Generics Market Revenue, by Drug Class, 2016 – 2026 (USD Billion)
        • 9.6.8.3. Rest of MEA Branded Generics Market Revenue, by Formulation Type, 2016 – 2026 (USD Billion)
        • 9.6.8.4. Rest of MEA Branded Generics Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
  • Chapter 10. Company Profiles
    • 10.1. Teva Pharmaceutical Industries Ltd.
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product portfulio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. *Same information will be provided for below mentioned companies*
      • 10.2.1. Mylan N.V
      • 10.2.2. Novartis AG
      • 10.2.3. Sun Pharmaceutical Industries Ltd.
      • 10.2.4. Pfizer Inc.
      • 10.2.5. Abbott Laboratories
      • 10.2.6. Aspen Pharmacare Hulding Ltd.
      • 10.2.7. Valeant Pharmaceuticals International, Inc.
      • 10.2.8. Others

Table Of Figures

List of Figures 

1. Global Branded Generics Market Segmentation by Therapeutic Application, Drug Class, Formulation Type, Distribution Channel and Geography
2. Global Branded Generics Market, 2018-2026 (USD Billion)
3. Porter’s Five Forces Analysis: Branded Generics Market
4. Global Branded Generics Market Attractiveness, by Therapeutic Application
5. Global Branded Generics Market Attractiveness, by Drug Class
6. Global Branded Generics Market Attractiveness, by Formulation Type
7. Global Branded Generics Market Attractiveness, by Distribution Channel
8. Global Branded Generics Market Attractiveness, by Regional
9. Global Branded Generics Market Revenue Share, by Therapeutic Application, 2019 & 2026 (USD Billion)
10. Global Branded Generics Market by Cardiovascular Diseases, 2016 – 2026 (USD Billion)
11. Global Branded Generics Market by Oncology, 2016 – 2026 (USD Billion)
12. Global Branded Generics Market by Diabetes, 2016 – 2026 (USD Billion)
13. Global Branded Generics Market by Gastrointestinal Diseases, 2016 – 2026 (USD Billion)
14. Global Branded Generics Market by Neurology, 2016 – 2026 (USD Billion)
15. Global Branded Generics Market by Analgesics and Anti-Inflammatory, 2016 – 2026 (USD Billion)
16. Global Branded Generics Market by Dermatology Diseases, 2016 – 2026 (USD Billion)
17. Global Branded Generics Market by Others, 2016 – 2026 (USD Billion)
18. Global Branded Generics Market Revenue Share, by Drug Class, 2019 & 2026 (USD Billion)
19. Global Branded Generics Market by Alkylating Agents, 2016 – 2026 (USD Billion)
20. Global Branded Generics Market by Hormones, 2016 – 2026 (USD Billion)
21. Global Branded Generics Market by Antimetabolites, 2016 – 2026 (USD Billion)
22. Global Branded Generics Market by Anti-Hypertensive, 2016 – 2026 (USD Billion)
23. Global Branded Generics Market by Anti-Depressants, 2016 – 2026 (USD Billion)
24. Global Branded Generics Market by Lipid Lowering Drugs, 2016 – 2026 (USD Billion)
25. Global Branded Generics Market by Anti-Epileptics, 2016 – 2026 (USD Billion)
26. Global Branded Generics Market by Anti-Psychotics, 2016 – 2026 (USD Billion)
27. Global Branded Generics Market by Others, 2016 – 2026 (USD Billion)
28. Global Branded Generics Market Revenue Share, by Formulation Type, 2019 & 2026 (USD Billion)
29. Global Branded Generics Market by Oral, 2016 – 2026 (USD Billion)
30. Global Branded Generics Market by Topical, 2016 – 2026 (USD Billion)
31. Global Branded Generics Market by Parenteral, 2016 – 2026 (USD Billion)
32. Global Branded Generics Market by Others, 2016 – 2026 (USD Billion)
33. Global Branded Generics Market Revenue Share, by Distribution Channel, 2019 & 2026 (USD Billion)
34. Global Branded Generics Market by Hospital Pharmacies, 2016 – 2026 (USD Billion)
35. Global Branded Generics Market by Online Pharmacies, 2016 – 2026 (USD Billion)
36. Global Branded Generics Market by Retail Pharmacies, 2016 – 2026 (USD Billion)
37. Global Branded Generics Market by Drug Stores, 2016 – 2026 (USD Billion)
38. Global Branded Generics Market Revenue Share, by Region, 2018-2026 (USD Billion)
39. North America Branded Generics Market, 2016-2026, (USD Billion)
40. Europe Branded Generics Market, 2016-2026, (USD Billion)
41. Asia Pacific Branded Generics Market, 2016-2026(USD Billion)
42. Latin America Branded Generics Market, 2016 – 2026 (USD Billion)
43. Middle East & Africa Branded Generics Market, 2016 – 2026, (USD Billion)


Table Of Tables

List of Tables

1. Global Branded Generics Market Snapshot
2. Drivers for Branded Generics Market: Impact Analysis
3. Restraints of Branded Generics Market: Impact Analysis
4. North America Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
5. North America Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
6. North America Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
7. North America Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
8. U.S. Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
9. U.S. Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
10. U.S. Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
11. U.S. Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
12. Canada Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
13. Canada Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
14. Canada Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
15. Canada Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
16. Mexico Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
17. Mexico Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
18. Mexico Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
19. Mexico Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
20. Europe Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
21. Europe Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
22. Europe Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
23. Europe Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
24. UK Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
25. UK Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
26. UK Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
27. UK Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
28. France Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
29. France Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
30. France Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
31. France Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
32. Germany Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
33. Germany Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
34. Germany Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
35. Germany Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
36. Italy Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
37. Italy Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
38. Italy Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
39. Italy Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
40. Spain Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
41. Spain Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
42. Spain Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
43. Spain Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
44. Russia Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
45. Russia Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
46. Russia Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
47. Russia Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
48. Rest of Europe Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
49. Rest of Europe Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
50. Rest of Europe Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
51. Rest of Europe Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
52. Asia Pacific Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
53. Asia Pacific Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
54. Asia Pacific Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
55. Asia Pacific Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
56. China Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
57. China Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
58. China Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
59. China Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
60. Japan Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
61. Japan Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
62. Japan Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
63. Japan Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
64. India Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
65. India Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
66. India Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
67. India Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
68. Australia Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
69. Australia Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
70. Australia Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
71. Australia Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
72. South Korea Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
73. South Korea Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
74. South Korea Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
75. South Korea Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
76. Rest of Asia Pacific Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
77. Rest of Asia Pacific Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
78. Rest of Asia Pacific Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
79. Rest of Asia Pacific Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
80. Latin America Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
81. Latin America Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
82. Latin America Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
83. Latin America Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
84. Brazil Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
85. Brazil Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
86. Brazil Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
87. Brazil Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
88. Argentina Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
89. Argentina Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
90. Argentina Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
91. Argentina Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
92. Rest of Latin America Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
93. Rest of Latin America Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
94. Rest of Latin America Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
95. Rest of Latin America Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
96. Middle East & Africa Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
97. Middle East & Africa Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
98. Middle East & Africa Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
99. Middle East & Africa Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
100. GCC Countries Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
101. GCC Countries Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
102. GCC Countries Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
103. GCC Countries Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
104. South Africa Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
105. South Africa Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
106. South Africa Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
107. South Africa Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
108. Rest of MEA Branded Generics Market Revenue, By Therapeutic Application, 2016 – 2026 (USD Billion) 
109. Rest of MEA Branded Generics Market Revenue, By Drug Class, 2016 – 2026 (USD Billion)
110. Rest of MEA Branded Generics Market Revenue, By Formulation Type, 2016 – 2026 (USD Billion)
111. Rest of MEA Branded Generics Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Off-invoice discounts would drive growth in the global branded generics market over the forecast period. Because of higher discounts offered by players, demand for branded generic drugs is expected to be strong in established markets such as the United States. In recent years, the global branded generics market has expanded at an unprecedented rate. Several intrinsic and extrinsic dynamics relating to licencing, production, and distribution characterise the pharmaceutical industry. The principle of patenting is highly useful in the pharmaceutical industry. Drugs patented to a specific company grant the entity legal rights to sell the product in the pharmaceutical industry. Furthermore, by patenting their products, pharmaceutical companies will remain unaffected by the emergence of numerous rivals in the industry. However, the idea of branded generics has grown in the pharmaceutical industry in recent years. Since branded generics can be off-patient, many pharmaceutical firms will bid to sell these drugs on the market.

According to Zion Market Research, the Branded Generics market is expected to generate revenue of around USD 453.63 Billion by the end of 2026, growing at a CAGR of 8.98%.

Latin America has emerged as a top priority for the pharmaceutical industry. The barriers to entry are smaller than in China and Russia. Significant disparities in healthcare systems, intellectual property structures, and emerging middle-class income, on the other hand, necessitate a country-by-country evaluation of attractiveness. The top six Latin American pharmaceuticals markets – Brazil, Mexico, Venezuela, Argentina, Colombia, and Chile – account for 80% of the industry, but their economic conditions vary greatly. Brazil and Mexico are the most stable and sought-after prospects, but they also necessitate significant investment. As a result, some multinational corporations have shifted their attention to medium-sized countries such as Columbia, which they are primarily entering through Mergers and Acquisitions (M&A). However, an industry consensus on the attractiveness of markets such as Colombia, Venezuela, and Argentina are yet to emerge, and several multinationals are still analysing the potential. Local businesses in Argentina, for example, can be extremely competitive and profitable, whereas multinational corporations struggle. As in all emerging markets, the secret to success is fully understanding local rules and customising the approach to local needs while capturing regional synergies.

The major players in the global branded generics market include Teva Pharmaceutical Industries Ltd., Mylan N.V, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Abbott Laboratories, Aspen Pharmacare Holding Ltd., and Valeant Pharmaceuticals International, Inc. among others.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed